The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 44.25
Bid: 44.00
Ask: 44.50
Change: -0.50 (-1.12%)
Spread: 0.50 (1.136%)
Open: 44.75
High: 44.25
Low: 44.20
Prev. Close: 44.75
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Hardman & Co Research: Avacta (AVCT): Wake-up call for the market

10 Dec 2018 07:30

Hardman & Co Research Hardman & Co Research: Avacta (AVCT): Wake-up call for the market 10-Dec-2018 / 07:30 GMT/BST


Hardman & Co: Wake-up call for the market

Avacta (AVCT) is a pre-clinical stage biotechnology company and the proprietary owner of Affimer technology. Affimers represent a radical alternative to the established antibody technology. The significant technical and commercial benefits of Affimers are being recognised increasingly through corporate and academic interest, ongoing evaluations, and deal flow. AVCT has just concluded an Affimer therapeutics development and commercial agreement with the global pharma company, LG Chem, worth up to $310m in upfront and milestone payments. This represents a huge endorsement of the Affimer platform.

Please click here for the full report:

https://www.hardmanandco.com/research/corporate-research/wake-up-call-for-the-market/

 

To contact us: Hardman & Co 35 New Broad Street London EC2M 1NH www.hardmanandco.comFollow us on Twitter @HardmanandCo Contacts: Dr Martin Hall Dr Dorothea Hill Dr Gregoire Pave +44 20 7194 7622 mh@hardmanandco.comdmh@hardmanandco.comgp@hardmanandco.com

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the world with high-quality research, investor engagement programmes and advisory services.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

755789 10-Dec-2018 

corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
23rd Apr 20204:40 pmRNSSecond Price Monitoring Extn
23rd Apr 20204:35 pmRNSPrice Monitoring Extension
23rd Apr 202010:18 amRNSResult of General Meeting
22nd Apr 20202:30 pmRNSHolding(s) in Company
22nd Apr 20209:05 amRNSSecond Price Monitoring Extn
22nd Apr 20209:00 amRNSPrice Monitoring Extension
22nd Apr 20207:00 amRNSAvacta/Cytiva Partnership Ahead of Schedule
20th Apr 20209:05 amRNSSecond Price Monitoring Extn
20th Apr 20209:00 amRNSPrice Monitoring Extension
17th Apr 20207:00 amRNSNotice of Results - Update
16th Apr 20204:41 pmRNSSecond Price Monitoring Extn
16th Apr 20204:36 pmRNSPrice Monitoring Extension
16th Apr 20202:05 pmRNSSecond Price Monitoring Extn
16th Apr 20202:00 pmRNSPrice Monitoring Extension
15th Apr 20209:05 amRNSSecond Price Monitoring Extn
15th Apr 20209:00 amRNSPrice Monitoring Extension
14th Apr 20205:30 pmRNSHolding(s) in Company
14th Apr 20202:06 pmRNSSecond Price Monitoring Extn
14th Apr 20202:00 pmRNSPrice Monitoring Extension
14th Apr 202011:05 amRNSSecond Price Monitoring Extn
14th Apr 202011:00 amRNSPrice Monitoring Extension
9th Apr 20204:41 pmRNSSecond Price Monitoring Extn
9th Apr 20204:37 pmRNSPrice Monitoring Extension
8th Apr 20202:05 pmRNSSecond Price Monitoring Extn
8th Apr 20202:00 pmRNSPrice Monitoring Extension
8th Apr 202011:05 amRNSSecond Price Monitoring Extn
8th Apr 202011:00 amRNSPrice Monitoring Extension
8th Apr 20209:05 amRNSSecond Price Monitoring Extn
8th Apr 20209:00 amRNSPrice Monitoring Extension
8th Apr 20207:00 amRNSAvacta & Cytiva Collaborate on COVID-19 Rapid Test
6th Apr 20205:45 pmRNSHolding(s) in Company
6th Apr 20202:06 pmRNSSecond Price Monitoring Extn
6th Apr 20202:01 pmRNSPrice Monitoring Extension
6th Apr 20207:00 amRNSProposed Placing to raise £3.75 million
2nd Apr 20207:01 amRNSAppointment of Joint Broker
2nd Apr 20207:00 amRNSSubscription to raise £2 million
26th Mar 202011:05 amRNSSecond Price Monitoring Extn
26th Mar 202011:00 amRNSPrice Monitoring Extension
24th Mar 20202:06 pmRNSSecond Price Monitoring Extn
24th Mar 20202:00 pmRNSPrice Monitoring Extension
16th Mar 20204:42 pmRNSSecond Price Monitoring Extn
16th Mar 20204:38 pmRNSPrice Monitoring Extension
10th Mar 20207:00 amRNSShareholder/Investor Meeting and Presentation
13th Feb 20207:00 amRNSNotice of Results
11th Feb 20207:00 amRNSShare Incentive Plan/Issue of Equity
3rd Feb 20207:00 amRNSAvacta and Daewoong Agreement
29th Jan 20202:45 pmRNSHolding(s) in Company
28th Jan 20207:00 amRNSSuccessful initial proof-of-concept
23rd Jan 20207:00 amRNSTrading Update
21st Jan 20207:00 amRNSDirector Appointment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.